Nasdaq · Healthcare

Beta Bionics, Inc. (BBNX)

As-reported financials and recent SEC filings for Beta Bionics, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.

Snapshot

Revenue

$100.3M

Net income

$-73.2M

Net margin

-73.0%

Diluted EPS

$-1.81

ROE

-25.5%

P/E (TTM)

—

Market cap

—

Debt / equity

—

Income statement (as reported)

Line	FY2025	FY2024	FY2024
Revenue	$100.3M	$65.1M	$12.0M
Gross profit	$55.5M	$35.9M	$6.3M
Operating income	$-71.7M	$-45.3M	$-35.9M
Net income	$-73.2M	$-54.8M	$-44.1M
Diluted EPS	$-1.81	$-1.43	$-1.39

Source: company XBRL financial statements on SEC EDGAR.

Recent SEC filings

4/A2026-07-02

42026-06-30

1442026-06-29

1442026-06-26

42026-06-25

42026-06-25

1442026-06-24

1442026-06-24

Largest Healthcare peers

UNH

UNITEDHEALTH GROUP INC

All Healthcare companies →

Go deeper on BBNX

Search Beta Bionics, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.

Start free

Or check your whole portfolio free — no account needed.

Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.